VANCOUVER, Nov. 26 /PRNewswire-FirstCall/ - Biotech Holdings reports that it has signed an agreement (the "Agreement") with a private company (the "UAE Distributor"), pursuant to which, for a period of three years with an option to renew, the UAE Distributor will have an exclusive right to market and distribute Sucanon Type II Diabetes drug ("Sucanon") in the United Arab Emirates including Dubai.
Pursuant to the agreement, the UAE distributor will have the option of receiving Sucanon either in pre-mix form from Canada or in tableted form from the Company's contract tableter in Mexico.
The United Arab Emirates according to information quoted in the Globe and Mail newspaper November 14, 2007, page L6 and attributed to Diabetes Forecast magazine, published by the American Diabetes Association, has the world's second highest percentage of adults afflicted by Type II Diabetes, at 19.5 %, approximately one in five adults.
This release has been approved by the Board of Directors of Biotech Holdings Ltd.
Any statements made in this release that are not based on historical fact are forward-looking statements. Any forward-looking statements made in this release represent management's best judgement as to what may occur in the future. However, actual outcome and results are not guaranteed and are subject to certain risks, uncertainties and assumptions and may differ materially from what is expressed. There is no assurance that sales, once begun in any specific market, will be material.
CONTACT: Austin Rand at Biotech Holdings, 1-888-216-1111, or email@example.com. For background information on Biotech Holdings, or to receive news updates, see www.biotechltd.com
CONTACT: Austin Rand at Biotech Holdings, 1-888-216-1111, or
firstname.lastname@example.org. For background information on Biotech Holdings, or to
receive news updates, see www.biotechltd.com